Atchison RW, Castor BC, Harmon WM. Adenovirus-associated defective viral particles. science. 1965;149:754–6.
Calcedo R, Vandenberg LH, Gao G, Lin J, Wilson JM. Global epidemiology of adeno-associated virus neutralizing antibodies. J Infectious diseases. 2009;199:381-90.
Kruzik A, Fetahagic D, Hartlieb B, Dorn S, Koppensteiner H, Horling FM, Scheiflinger F, Reipert BM, de la Rosa M. Prevalence of anti-adeno-associated virus immune responses in an international cohort of healthy donors. Mol Ther Method Clinical Development. 2019;14:126–33.
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clade of adeno-associated viruses are widespread in human tissues. J Verrol. 2004;78:6381–8.
Meier AF, Fraefel C, Seyffert M. Interactions between adeno-associated viruses and their helper viruses. Virus 2020, 12.
Hasty E, Samulski RJ. 50 Years of Adeno-Associated Virus: A Golden Anniversary of Discovery, Research, and Gene Therapy Success—A Personal Perspective. Well, Gene Searle. 2015;26:257–65.
Luo Jie, Luo Y, Sun J, Zhou Y, Zhang Y, Yang X. Adeno-associated virus-mediated gene therapy for cancer: Current status. Cancer Letters. 2015;356:347–56.
Nieto K, Salvetti A. AAV-vectored vaccines against infectious diseases. Pre-Immunology. 2014;5:5.
Issa SS, Shaymadanova AA, Solovyeva VV, Rizvanov AA. Various AAV serotypes and their use in gene therapy: an overview. Cell 2023, 12.
Kim SJ. Eladocagene Exuparvovec: First approval. poison. 2022;82:1427–32.
Santa Ana TB, Araujo, NM. Adeno-associated virus infections and their impact on human health: an overview. Verol J. 2022;19:173.
Raj K, Ogston P, Beard P. Virus-mediated killing of cells lacking p53 activity. nature. 2001;412:914–7.
Hermonat PL. Adeno-associated virus inhibits human papillomavirus type 16: a viral interaction associated with cervical cancer. Cancer Res 1994;54:2278–81.
Hermonat PL, Plott RT, Santin AD, Parham GP, Flick JT. Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes via a human papillomavirus 16-ras type chimera. Gynecologic Oncology. 1997;66:487-94.
Waltz CM, Correa-Ochoa MM, Mueller M, Schlehofer JR. Adeno-associated virus type 2 induces repression of the human papillomavirus type 18 promoter in transgenic mice. virology. 2002;293:172-81.
Coker AL, Russell RB, Bond SM, Pirisi L, Liu Y, Mane M, Kokorina N, Gerasimova T, Hermonat PL. Adeno-associated virus is associated with a lower risk of high-grade cervical tumors. Experimental Molecular Pathology. 2001;70:83-9.
Freitas LB, Tonani de Matos A, Lima BM, Miranda AE, Spano LC. Adeno-associated virus may exert a protective effect against cervical lesions caused by human papillomavirus, independent of HIV serostatus. International Journal of STDs and AIDS. 2012;23:258–61.
Georg-Fries B, Biederlack S, Wolf J, zur Hausen H. Protein, helper dependence, and seroepidemiological analysis of novel human parvoviruses. virology. 1984;134:64-71.
La Bella T, Imbeaud S, Peneau C, Mami I, Datta S, Bayard Q, Caruso S, Hirsch TZ, Calderaro J, Morcrette G, et al. Adeno-associated viruses in the liver: natural history and consequences of tumor development. Intestine. 2020;69:737–47.
Nault JC, Datta S, Imbeaud S, Franconi A, Mallet M, Couchy G, Letouze E, Pilati C, Verret B, Blanc JF, et al. Recurrent AAV2-related insertional mutations in human hepatocellular carcinoma. Nat Genette. 2015;47:1187–93.
Tatsuno K, Midorikawa Y, Takayama T, Yamamoto S, Nagae G, Moriyama M, Nakakawa H, Koike K, Moriya K, Aburatani H. Impact of AAV2 and hepatitis B virus integration into the genome on the development of hepatocellular carcinoma in patients with previous hepatitis B virus infection. Clin Cancer Res 2019;25:6217–27.
Chandler RJ, LaFave MC, Varshney GK, Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V, Elcaron AG, Burge Si SM, Venditti CP. Vector design affects liver genotoxicity following adeno-associated virus gene therapy. J Clin Invest. 2015;125:870–80.
Donsante A, Miller DG, Li Y, Vogler C, Brunt EM, Russell DW, Sands MS. AAV vector integration sites in mouse hepatocellular carcinoma. science. 2007;317:477.
Sabatino DE, Bushman FD, Chandler RJ, Crystal RG, Davidson BL, Dolmetsch R, Eggan KC, Gao G, Gil-Farina I, Kay MA, et al. Assessing the scientific status of adeno-associated virus integration: an integrative perspective. moorsel. 2022;30:2646–63.
Ho A, Orton R, Tayler R, Asamaphan P, Herder V, Davis C, Tong L, Smollett K, Manali M, Allan J, et al. Adeno-associated virus 2 infection in children with non-AE hepatitis. Nature 2023.
Morfopoulou S, Buddle S, Montaguth OET, Atkinson L, Guerra-Assuncao JA, Marjaneh MM, Chiozzi RZ, Storey N, Campos L, Hutchinson JC, et al. Genomic study of unexplained acute hepatitis in children. Nature 2023.
Servelita V, Gonzalez AS, Lamson DM, Foresythe A, Huh HJ, Bazinet AL, Bergman NH, Bull RL, Garcia KY, Goodrich JS, et al. Adeno-associated virus type 2 in children with acute severe hepatitis in the United States. Nature 2023.
World Health Organization. : Severe acute hepatitis of unknown etiology in children – multinational (https://www.who.int/emergcies/disease-outbreak-news/item/2022-DON400).
Blackwell JM, Jamieson SE, Burgner D. HLA and infectious diseases. Clin Microbiol Rev 2009;22:370–85. Table of contents.
Lumley SF, Richens N, Lees E, Cregan J, Kalimeris E, Oakley S, Morgan M, Segal S, Dawson M, Walker AS, et al. Changes in respiratory infections in children in UK teaching hospitals 2016-2021; impact of the SARS-CoV-2 pandemic. J infection. 2022;84:40–7.
Matthews PC, Campbell C, Sandulescu O, Maticic M, Ruta SM, Rivero-Juarez A, van Welzen BJ, Tan BK, Garcia F, Gherlan GS, et al. Outbreak of acute severe hepatitis in children: a perfect storm. What do we know, and what questions remain? Prepharmacology. 2022;13:1062408.
Gates S, Andreani J, Dewar R, Smith DB, Templeton K, Child HT, Breuer J, Golubchik T, Bassano I, Wade MJ, et al. A post-pandemic rebound in adeno-associated virus type 2 (AAV2) infection has been tentatively linked to an outbreak of unexplained severe acute hepatitis in children in the UK. J Med Virol. 2023;95:e28921.